---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Access and distribution"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Access and distribution. Topics: Manufacturing by third parties for clinical and commercial supply; U.S. commercial infrastructure, pricing, and reimbursement still to be established; Pre-commercial preparation, 2025 to 2026; Company market access goal: monotherapy and combination use; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/access-and-distribution"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Manufacturing by third parties for clinical and commercial supply

> “We rely completely on third parties to manufacture our pre-clinical and clinical drug supplies and we intend to rely on third parties to produce commercial supplies of any approved product candidate.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.11-2"></a>

### U.S. commercial infrastructure, pricing, and reimbursement still to be established

> “Furthermore, even if we or our current or future collaborators obtain regulatory approval for lanifibranor, we will still need to develop a commercial infrastructure, or otherwise develop relationships with collaborators to commercialize, establish a commercially viable pricing structure and obtain coverage and adequate reimbursement from third-party payors, including any government healthcare programs.”
> “We may collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-2.1.2.11-3"></a>

### Pre-commercial preparation, 2025 to 2026

> “Our regulatory and commercial infrastructure is advancing in lockstep, to position us to act with speed and conviction once we have the trial data.”

Source: [Inventiva full year 2025 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-results-2025-EN-03-30-2026-1.pdf)

> “Marketing and business development expenses amounted to €2.6 million for the first half of 2026, compared to €0.7 million for the same period in 2025, primarily reflecting increased personnel costs and expenses related to preparations for the potential commercial development of lanifibranor, if approved.”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.2.11-4"></a>

### Company market access goal: monotherapy and combination use

> “Demonstrate lanifibranor’s value as monotherapy and in combination to secure broad and rapid market access”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-2.1.2.11-5"></a>

### Commercialization rights in Greater China: CTTQ

> “Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the development and commercialization of lanifibranor in Greater China”

Source: [Inventiva Sino Biopharm license release (2022)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-Sino-Biopharm-Licensing-Agreement-EN-21-09-2022-1.pdf)

> “On September 21, 2022, we entered into the CTTQ License Agreement with CTTQ to develop and commercialize lanifibranor in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan, or each a CTTQ Region.”
> “Under the terms of the CTTQ License Agreement, CTTQ has the sole right and is solely responsible for all aspects of the commercialization of the Licensed Products in the CTTQ Territory, subject to regulatory approval, including (i) developing and executing a commercial launch and pre-launch plan, (ii) negotiating the price and reimbursement statuses of the Licensed Products with applicable governmental authorities”
> “We shall own and retain all right, title and interest in and to all trademarks, logos and trade names associate with any Licensed Product worldwide and have the sole right to register and maintain all such trademarks, logos and trade names worldwide.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

> “Revenue recognized in the first half of 2025 was attributable to the 2022 License Agreement with Chia Tai Tianging Pharmaceutical Group Co., Ltd. (as amended and assigned to Chia Tai Tianging (Guangzhou) Co., Ltd).”

Source: [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf)

<a id="topic-2.1.2.11-6"></a>

### Commercialization rights in Japan and South Korea: Hepalys Pharma

> “Hepalys Pharma, Inc., a company incorporated in Japan and incubated by Catalys Pacific, have entered into an exclusive licensing agreement (the “Agreement”) to develop and commercialize Inventiva’s proprietary drug candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.”

Source: [Inventiva Hepalys license release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Japan-Licensing-Agreement-EN-09-20-2023-1.pdf)

<a id="topic-2.1.2.11-7"></a>

### Specialty pharmacy or distribution network

No evidence found.

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
